154257-85-9

Basic information

• Product Name: 3-Bromo-5-chlorophenylethanone
• Synonyms: 1-(3-Bromo-5-chlorophenyl)ethanone;3-Bromo-5-chloroacetophenone;3-Bromo-5-chlorophenylethanone
• CAS NO: 154257-85-9
• Molecular Formula: C₈H₆BrClO
• Molecular Weight: 233.49
• Mol File: 154257-85-9.mol

Chemical Properties

• Boiling Point: 297.4°C at 760 mmHg
• Flash Point: 133.7°C
• Appearance: /
• Density: 1.566
• Vapor Pressure: 0.00135mmHg at 25°C
• Refractive Index: 1.571
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-Bromo-5-chlorophenylethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-chlorophenylethanone(154257-85-9)
• EPA Substance Registry System: 3-Bromo-5-chlorophenylethanone(154257-85-9)

Safety Data

• Hazardous Substances Data: 154257-85-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-chlorophenylethanone is utilized as a key intermediate in the synthesis of various drugs and pharmaceuticals, contributing to the development of new medications and therapeutic agents.
Used in Medicinal Chemistry:
3-Bromo-5-chlorophenylethanone serves as a building block for the synthesis of other biologically active compounds, playing a crucial role in the advancement of medicinal chemistry by enabling the creation of novel and effective pharmaceuticals.
Used in Material Science:
3-Bromo-5-chlorophenylethanone has been investigated for its potential use in the development of new materials, indicating its versatility beyond pharmaceutical applications and extending into material science for innovative uses.
It is imperative to handle 3-Bromo-5-chlorophenylethanone with care due to its potential hazards and toxic properties, ensuring safety in its application and synthesis processes.

InChI:InChI=1/C8H6BrClO/c9-7-3-6(1-2-11)4-8(10)5-7/h2-5H,1H2

Upstream product

• 14862-52-3 1,3-dibromo-5-chlorobenzene 
• 78191-00-1 N-Methoxy-N-methylacetamide 
• 75-16-1 methylmagnesium bromide 
• 42860-02-6 3‐bromo‐5‐chlorobenzoic acid 
• 97674-02-7 tributyl(1-ethoxyvinyl)stannane 

Downstream Products

• 1541198-37-1 C₁₀H₉BrClF₃O₃S 
• 1541198-38-2 C₁₀H₉BrClF₃ 
• 1541198-39-3 C₁₁H₁₀ClF₃O 
• 1541198-35-9 rac-ethyl 3-amino-3-(3-chloro-5-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl)propanoate 
• 1541199-38-5 (S)-3-amino-3-(3-chloro-5-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl)propanoic acid 
• 1541199-39-6 (R)-ethyl 3-amino-3-(3-chloro-5-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl)propanoate 
• 1541199-37-4 (S)-ethyl 3-amino-3-(3-chloro-5-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl)propanoate hydrochloride 
• 1541199-40-9 (3S)-ethyl 3-(3-chloro-5-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoate 
• 1541197-38-9 (3S)-3-(3-chloro-5-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl)-3-(2-(3-hydroxy-5-((5-hydroxy-1,4,5,6-tetrahydropyrimidin-2-yl)amino)benzamido)acetamido)propanoic acid 
• 950225-58-8 3-acetyl-5-chlorobenzoate 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO

This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, compositions containing such molecules, and processes of using such molecules and compositions against such pests. These molecules and compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS

Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.